ArticlePloS one2026
Disease burden and prediction of liver cancer attributable to metabolic risks in five East Asian countries from 1990 to 2023.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer is a major public health issue in five East Asian countries, with metabolic factors becoming primary drivers. Based on the Global Burden of Disease (GBD) 2023 database, we extracted the total number and age-standardized mortality rates, years lived with disability (YLDs), years of life lost (YLLs) and disability-adjusted life years (DALYs) related to liver cancer attributable to metabolic risks (LC-MR). We analyzed the disease burden of LC-MR and trends across five East Asian countries from 1990 to 2023, examining patterns by sex and age as well as key drivers across different nations, and projected future trends through 2053. In 2023, Mongolia exhibited the highest age-standardized rates for LC-MR, while China ranked first in the total absolute number of cases. From 1990 to 2023, the overall disease burden showed a downward trend in Japan and Republic of Korea, whereas an upward trend was observed in Mongolia, Democratic People's Republic of Korea, and China. Significant sex and age disparities were observed across all countries in that males bore a higher burden and the burden generally shifted towards the elderly population. Decomposition analysis revealed that the changes in disease burden in Japan and Republic of Korea were primarily driven by population ageing, whereas the main drivering factors were epidemiological changes and population growth in Mongolia and Democratic People's Republic of Korea. Projections of disease burden for 2053 indicate that the disparities among countries would further widen. Therefore, strengthening metabolic risk interventions and implementing targeted prevention strategies for high-risk populations, especially the aging population, is crucial for reducing the regional burden of LC-MR, given the risk disparities across different countries.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.